196 related articles for article (PubMed ID: 36066547)
1. Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.
Wenger TL; Ganti S; Bull C; Lutsky E; Bennett JT; Zenner K; Jensen DM; Dmyterko V; Mercan E; Shivaram GM; Friedman SD; Bindschadler M; Drusin M; Perkins JN; Kong A; Bly RA; Dahl JP; Bonilla-Velez J; Perkins JA
Genet Med; 2022 Nov; 24(11):2318-2328. PubMed ID: 36066547
[TBL] [Abstract][Full Text] [Related]
2. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.
Morin G; Degrugillier-Chopinet C; Vincent M; Fraissenon A; Aubert H; Chapelle C; Hoguin C; Dubos F; Catteau B; Petit F; Mezel A; Domanski O; Herbreteau G; Alesandrini M; Boddaert N; Boutry N; Broissand C; Han TK; Branle F; Sarnacki S; Blanc T; Guibaud L; Canaud G
J Exp Med; 2022 Mar; 219(3):. PubMed ID: 35080595
[TBL] [Abstract][Full Text] [Related]
3. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).
Canaud G; Lopez Gutierrez JC; Irvine AD; Vabres P; Hansford JR; Ankrah N; Branle F; Papadimitriou A; Ridolfi A; O'Connell P; Turner S; Adams DM
Genet Med; 2023 Dec; 25(12):100969. PubMed ID: 37634128
[TBL] [Abstract][Full Text] [Related]
4.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
5. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations.
Brouillard P; Schlögel MJ; Homayun Sepehr N; Helaers R; Queisser A; Fastré E; Boutry S; Schmitz S; Clapuyt P; Hammer F; Dompmartin A; Weitz-Tuoretmaa A; Laranne J; Pasquesoone L; Vilain C; Boon LM; Vikkula M
Orphanet J Rare Dis; 2021 Jun; 16(1):267. PubMed ID: 34112235
[TBL] [Abstract][Full Text] [Related]
6. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C
Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800
[TBL] [Abstract][Full Text] [Related]
7. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
[TBL] [Abstract][Full Text] [Related]
8. Early diagnosis enabling precision medicine treatment in a young boy with PIK3R1-related overgrowth.
Schönewolf-Greulich B; Karstensen HG; Hjortshøj TD; Jørgensen FS; Harder KM; Frevert S; Hove H; Diness BR
Eur J Med Genet; 2022 Oct; 65(10):104590. PubMed ID: 35964931
[TBL] [Abstract][Full Text] [Related]
9. Alpelisib administration reduced lymphatic malformations in a mouse model and in patients.
Delestre F; Venot Q; Bayard C; Fraissenon A; Ladraa S; Hoguin C; Chapelle C; Yamaguchi J; Cassaca R; Zerbib L; Magassa S; Morin G; Asnafi V; Villarese P; Kaltenbach S; Fraitag S; Duong JP; Broissand C; Boccara O; Soupre V; Bonnotte B; Chopinet C; Mirault T; Legendre C; Guibaud L; Canaud G
Sci Transl Med; 2021 Oct; 13(614):eabg0809. PubMed ID: 34613809
[TBL] [Abstract][Full Text] [Related]
10. Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome.
López Gutiérrez JC; Lizarraga R; Delgado C; Martínez Urrutia MJ; Díaz M; Miguel M; Triana P
J Pediatr Adolesc Gynecol; 2019 Dec; 32(6):648-650. PubMed ID: 31330249
[TBL] [Abstract][Full Text] [Related]
11. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
12. Clinical and genetic analyses of patients with lateralized overgrowth.
Kim YM; Lee Y; Choi Y; Choi IH; Heo SH; Choi JM; Do HS; Jang JH; Yum MS; Yoo HW; Lee BH
BMC Med Genomics; 2022 Sep; 15(1):206. PubMed ID: 36175890
[TBL] [Abstract][Full Text] [Related]
13. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.
Singh S; Bradford D; Li X; Mishra-Kalyani PS; Shen YL; Wang L; Zhao H; Xiong Y; Liu J; Charlab R; Kraft J; Khasar S; Miller CP; Rivera DR; Kluetz PG; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2024 Jan; 30(1):23-28. PubMed ID: 37624421
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.
Forde K; Resta N; Ranieri C; Rea D; Kubassova O; Hinton M; Andrews KA; Semple R; Irvine AD; Dvorakova V
Orphanet J Rare Dis; 2021 Feb; 16(1):109. PubMed ID: 33639990
[TBL] [Abstract][Full Text] [Related]
16. Response to Alpelisib in Clinically Distinct Pediatric Patients With PIK3CA -related Disorders.
Kolitz E; Fernandes NJ; Agim NG; Ludwigl K
J Pediatr Hematol Oncol; 2022 Nov; 44(8):482-485. PubMed ID: 35129141
[TBL] [Abstract][Full Text] [Related]
17. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
19. [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q; Canaud G
Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]